Dr. Marcelo DaSilva: Mesothelioma and Thoracic Surgery Specialist

Dr. Marcelo DaSilva is a thoracic surgeon with a concentrated clinical focus on pleural mesothelioma and other asbestos-related thoracic malignancies. Patients diagnosed with mesothelioma, a rare and aggressive cancer caused almost exclusively by asbestos exposure, often face a confusing and emotionally overwhelming search for qualified specialists. Dr. DaSilva represents one of a small cohort of surgeons in the United States who have dedicated a significant portion of their practice to this disease, which the American Cancer Society estimates accounts for roughly 3,000 new diagnoses annually in the U.S.

Thoracic surgeons who specialize in mesothelioma occupy a critical role in the treatment landscape. Surgery is not appropriate for every patient, but for those with early-stage disease and adequate cardiopulmonary reserve, surgical resection, particularly pleurectomy/decortication (P/D), can extend survival and meaningfully improve quality of life. According to the National Cancer Institute, multimodal approaches combining surgery with chemotherapy regimens such as cisplatin plus pemetrexed remain the standard of care for eligible patients. Dr. DaSilva's practice is built around this multimodal philosophy.

What sets mesothelioma specialists apart from general thoracic surgeons is volume and experience. A 2018 analysis published in the Annals of Thoracic Surgery found that outcomes for complex pleural procedures, including P/D and extrapleural pneumonectomy (EPP), were significantly better at high-volume centers where surgeons performed these operations regularly. Patients seeking a mesothelioma specialist should ask specifically about a surgeon's annual case volume, their preferred surgical approach, and their institutional support structure, including access to oncologists, pulmonologists, and radiation oncologists experienced with this disease.

As one perspective shared within the mesothelioma specialist community puts it: "The difference between a surgeon who has done five mesothelioma cases and one who has done five hundred isn't just technical. It's the ability to read the disease, anticipate complications, and know when not to operate." That philosophy of patient selection and individualized care is central to how specialists like Dr. DaSilva approach this complex malignancy.

When a patient is referred to a thoracic surgeon like Dr. DaSilva, the diagnostic workup is typically already underway, but a mesothelioma specialist will often want to confirm or refine the pathological diagnosis before recommending a surgical approach. Mesothelioma is notoriously difficult to diagnose accurately. The disease can mimic other pleural conditions, including metastatic adenocarcinoma and benign pleural disease, and misdiagnosis rates have historically been high. A 2020 review in Translational Lung Cancer Research noted that immunohistochemical panels, including markers such as calretinin, WT-1, and D2-40, are essential to confirm epithelioid, sarcomatoid, or biphasic histology, each of which carries different prognostic implications and surgical considerations.

A specialist's diagnostic evaluation typically includes a review of prior biopsy materials, often with re-reading by an experienced mesothelioma pathologist. Imaging studies, particularly contrast-enhanced CT of the chest and abdomen, PET scanning, and in some cases MRI, help characterize the extent of disease and identify potential contraindications to surgery. Pulmonary function testing is critical before any major thoracic resection, as patients must have sufficient lung reserve to tolerate the procedure. According to the National Comprehensive Cancer Network (NCCN) guidelines for mesothelioma, staging via the 8th edition TNM system guides surgical candidacy decisions, with Stage I and II patients generally considered most appropriate for curative-intent resection.

Dr. DaSilva and surgeons at similar centers may also use diagnostic thoracoscopy, a minimally invasive procedure using a small camera inserted into the chest cavity, to directly visualize tumor extent and obtain additional tissue samples when prior biopsies have been inconclusive. This step can prevent patients from undergoing a major open surgery only to find disease that is more advanced than imaging suggested.

Imagine a 62-year-old retired shipyard worker who arrives at a specialist's office carrying a CT scan showing a thickened right pleural lining and a small pleural effusion. His pathology report confirms epithelioid mesothelioma, the most favorable histological subtype. His pulmonary function tests show preserved lung capacity. For this patient, a mesothelioma surgical specialist like Dr. DaSilva would likely discuss pleurectomy/decortication, a lung-sparing operation that removes the pleural lining and all visible tumor while preserving the underlying lung. This contrasts with the more radical extrapleural pneumonectomy, which removes the entire lung along with the pleura, pericardium, and diaphragm.

The surgical approach to mesothelioma has evolved considerably over the past two decades. The landmark MARS trial, published in The Lancet Oncology in 2011, raised significant questions about the survival benefit of EPP in an unselected patient population, contributing to a broader shift in the field toward P/D for appropriately selected patients. More recent data, including a 2021 analysis from Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic and Cardiovascular Surgery, suggested that extended P/D could achieve median survival times exceeding 20 months in epithelioid mesothelioma patients, a meaningful improvement over historical benchmarks.

Beyond surgery itself, the multimodal treatment framework that specialists like Dr. DaSilva employ typically includes systemic chemotherapy, most commonly the cisplatin plus pemetrexed combination approved by the FDA in 2004, and increasingly, immunotherapy. The FDA's 2020 approval of nivolumab plus ipilimumab (Opdivo plus Yervoy) as a first-line treatment for unresectable pleural mesothelioma, based on the CheckMate 743 trial results published in The Lancet, has added an important option for patients who are not surgical candidates or who experience recurrence after surgery. Radiation therapy, particularly intensity-modulated radiation therapy (IMRT) delivered to the hemithorax after EPP, has also been integrated into some institutional protocols, though its role remains an area of active investigation.

Patients treated at centers with dedicated mesothelioma programs benefit from tumor boards, multidisciplinary meetings where surgeons, medical oncologists, radiation oncologists, and pulmonologists review each case together before recommending a treatment plan. This collaborative structure, rather than any single physician's expertise alone, is what defines a true mesothelioma specialty center.

Prognosis in mesothelioma depends on several well-established factors, and understanding these can help patients have more informed conversations with specialists like Dr. DaSilva. According to the American Cancer Society, the overall five-year survival rate for pleural mesothelioma remains approximately 10%, reflecting the disease's aggressive nature and the fact that most patients are diagnosed at advanced stages. However, these population-level statistics don't capture the full picture for patients who are surgical candidates with favorable tumor characteristics.

Histological subtype is one of the strongest prognostic variables. Epithelioid mesothelioma, which accounts for roughly 50 to 70% of cases according to the NCI, carries the most favorable prognosis, with some series reporting median survival exceeding 18 to 24 months with aggressive multimodal therapy. Sarcomatoid mesothelioma, by contrast, is associated with a median survival of less than six months in most published series, and most surgical specialists do not recommend resection for this subtype. Biphasic tumors fall between these extremes, with prognosis influenced by the relative proportion of each component.

Stage at diagnosis, performance status, and the presence or absence of lymph node involvement also significantly influence outcomes. A 2019 study in JAMA Oncology examining outcomes across 13,000 mesothelioma patients in the National Cancer Database found that patients treated at academic medical centers with higher surgical volumes had statistically significant improvements in overall survival compared to those treated at community hospitals, reinforcing the importance of seeking out experienced specialists.

Consider a patient who has just completed surgery and initial chemotherapy under the care of a mesothelioma specialist. The treatment itself may be over, but living with a mesothelioma diagnosis, and navigating what comes after, presents its own set of challenges. Specialists like Dr. DaSilva typically work within programs that connect patients to palliative care teams, social workers, and patient navigators who can help manage symptoms, coordinate follow-up imaging, and connect patients with support resources.

Follow-up after mesothelioma treatment is intensive. Most programs recommend CT imaging of the chest and abdomen every three to four months for the first two years after treatment, transitioning to every six months thereafter if the patient remains disease-free. Recurrence is unfortunately common even after successful surgical resection, and patients should understand that the relationship with their specialist is likely to be long-term. Clinical trials represent an important option at recurrence, and mesothelioma specialists typically have connections to active trials through institutions like the NCI-designated cancer centers or cooperative oncology groups such as SWOG and ECOG-ACRIN.

The legal and financial dimensions of mesothelioma care are also significant. Because the disease is almost always caused by occupational or environmental asbestos exposure, many patients are eligible for compensation through asbestos trust funds or civil litigation. Mesothelioma specialists often work in environments where patient navigators can facilitate referrals to legal resources, though the medical and legal processes remain entirely separate. According to RAND Corporation research published in 2021, asbestos trust funds have paid out more than $20 billion in compensation to claimants since the 1980s, representing a significant resource for patients facing the financial burden of treatment.